GLOBAL SURVEY FACT SHEET



Similar documents
REPORT: Improving Physician-Patient Dialogue About Multiple Sclerosis Around the World

What is Multiple Sclerosis? Gener al information

Life with MS: Mastering Early Treatment

2.1 Who first described NMO?

LONG TERM HYPERBARIC OXYGENATION (HBO) RETARDS PROGRESSION IN MULTIPLE SCLEROSIS PATIENTS

GENENTECH S OCRELIZUMAB FIRST INVESTIGATIONAL MEDICINE TO SHOW EFFICACY IN PEOPLE WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN LARGE PHASE III STUDY

AUBMC Multiple Sclerosis Center

Clinical Trials Need More Subjects

Multiple Sclerosis & MS Ireland Media Fact Sheet

Understanding. Multiple Sclerosis. Tim, diagnosed in 2004.

About MS. An introduction to. An introduction to multiple sclerosis for people who have recently been diagnosed. What is MS? Is it common?

The rising cost of prescription drugs to treat multiple sclerosis in upstate New York

A Definition of Multiple Sclerosis

Trauma Insurance Claims Seminar Invitation

Supporting MS-Related Disability Claims to Private Insurers: The Physician s Role

Life with MS: Mastering Relationships with Family and Friends

Understanding Relapse in Multiple Sclerosis. A guide for people with MS and their families

06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute

Muscular Dystrophy and Multiple Sclerosis. ultimately lead to the crippling of the muscular system, there are many differences between these

Optic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain.

Global Multiple Sclerosis Market: Trends and Opportunities ( )

Many people with MS use some form of conventional medical treatment, and many people also use complementary and alternative medicine (CAM).

Multiple Sclerosis Society of Canada. CADA Presentation May 4, 2011

Policy proposals to improve access to multiple sclerosis treatments in Europe

Biogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest

ADULT HEALTH AND WELLBEING LONG-TERM NEUROLOGICAL CONDITIONS

Multiple Sclerosis: What You Need To Know. For Professionals

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

Progress in MS: Current and Emerging Therapies

Multiple Sclerosis (MS)

Putting the Cart Back Behind the Horse: Converting a population based research database into an electronic clinical patient record

Multiple Sclerosis Ireland, September Contents Summary 2 Commentary 3 Recommendations 5 Information on MS 6 Personal testimonies 9

Sexuality Issues in MS Nursing

Global Economic Impact of Multiple Sclerosis

Spine Care Centre (SCC) protocols for Multiple Sclerosis Update 1 August 2015

New perception of disability including cognition, fatigue, pain and other impairments related to MS

Understanding your Tecfidera treatment

Understanding your Tecfidera treatment

387

Mellen Center for Multiple Sclerosis

Testimony of Timothy Coetzee, Ph.D. Representative of a Patient Advocacy Organization President, Fast Forward LLC

Global Gender Pay Gap Survey. United States, Canada, United Kingdom, France, Germany, The Netherlands, Switzerland

College Survey for Students with Brain Injury

1: Motor neurone disease (MND)

Wellness for People with MS: What do we know about Diet, Exercise and Mood And what do we still need to learn? March 2015

Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization N = 50

National Hospital for Neurology and Neurosurgery. Managing Spasticity. Spasticity Service

Global Multiple Sclerosis Epidemiology and Patient Flow Analysis

Multiple sclerosis (MS)

Rx Atlas. The Canadian. Third Edition. The following pages are an excerpt from. December 2013

MS Learn Online Feature Presentation Invisible Symptoms in MS Featuring Dr. Rosalind Kalb

CBT IN THE CITY. adjusted to the news of being with MS? April Experts at your fingertips call now. Check out our new services in you local area

TYSABRI Risk Management Plan. Carmen Bozic, MD Vice President Drug Safety and Risk Management Biogen Idec Inc

International Journal of Economics, Commerce and Management United Kingdom Vol. II, Issue 2, 2014

Which injectable medication should I take for relapsing-remitting multiple sclerosis?

ß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate

Patient Group Input to CADTH

MULTIPLE SCLEROSIS. Megan Snyder INTRODUCTION TO EPIDEMOLOGY

Elizabeth A. Crocco, MD Assistant Clinical Professor Chief, Division of Geriatric Psychiatry Department of Psychiatry and Behavioral Sciences Miller

REHABILITATION. begins right here

ALL ABOUT SPASTICITY. Solutions with you in mind

Stage A & C Sample Data Collection Form

REHABILITATION MEDICINE by PROFESSOR ANTHONY WARD

2013 Diabetes and Eye Disease Fact Sheet

Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU

MS: from disease management to patient management

Managing the Symptoms of Multiple Sclerosis. Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner

Lewy body dementia Referral for a Diagnosis

Knowledge Brochure Series MS & BUILDING A SUPPORT NETWORK

Altarum Institute Survey of Consumer Health Care Opinions. Fall Wendy Lynch, PhD Kristen Perosino, MPH Michael Slover, MS

Non-epileptic seizures

Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis

ATTITUDES AND PERCEPTIONS OF PROSPECTIVE INTERNATIONAL STUDENTS

Get the whole story about Critical Illness and how this could affect you

MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA

Consultation Response Statement of Best Practice for Critical Illness Cover 2009 Review Consultation Paper Association of British Insurers

Summary Diagnosis and Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in People with Multiple Sclerosis (MS)

Multiple Sclerosis & Income Security. The need is now

MULTIPLE SCLEROSIS. Mary Beth Rensberger, RN, BSN, MPH Author

Transcription:

Multiple sclerosis (MS) is a chronic, often disabling, disease that attacks the central nervous system, which is made up of the brain, spinal cord, and optic nerves. Symptoms may be mild or severe, ranging from numbness in the limbs to paralysis or loss of vision. The progression, severity, and specific symptoms of MS are unpredictable and vary from one person to another. GLOBAL SURVEY FACT SHEET MS is estimated to affect approximately 2.3 million people worldwide,i with an estimated 500,000 sufferers in the European Unionii and 400,000 in the United States.iii UNITED STATES 511 MS 200 UNITED KINGDOM 125 MS 150 GERMANY 146 MS 200 SPAIN ITALY 100 MS 150 100 MS 200 TOTAL 982 MS PATIENTS 900 NEUROLOGISTS STATE OF MS SURVEY The State of MS survey is a global assessment of the needs, experiences, and attitudes of people living with MS and neurologists who treat the disease in five countries (Germany, Italy, Spain, the United Kingdom, and the United States). The purpose is to better understand the current MS experience worldwide, including an assessment of communication between patients and physicians. Survey development was guided by the State of MS Consortium, an international steering committee composed of neurologists and patient advocacy group representatives. As part of its ongoing commitment to the MS community, Biogen Idec commissioned Harris Poll to conduct the State of MS survey in an effort to identify new and innovative solutions to improve care for MS patients. 1

PATIENT DEMOGRAPHICS iv GENDER BASE n=982 37% MALE 63% FEMALE TYPE BASE n=982 FIRST DIAGNOSED BASE n=982 Relapsing- Remitting MS Mean: 10.8 years Median: 8 years 63 % 4 2 Secondary- Progressive MS 3 % 37 % AGE BASE n=982 Mean: 44.9 11 % 2 % 5% Primary- Progressive MS 1 1 13 % 10 % 10% 18-29 years 27% 30-39 years 22 % 27 % 28% 40-49 years What type of MS are you currently diagnosed with? Progressive- Relapsing MS Other About how long ago were you first diagnosed with MS? 0 years 1-5 6-10 11-15 16-20 21-25 26-30 31+ 22% 50-59 years 13% 60+ years Not Sure Percentages may not always sum to total due to computer rounding. SURVEY METHODOLOGY Conducted online between 18 March 25 April 2014 Included MS patients 18 years of age or older in Germany, Italy, Spain, the United Kingdom (UK), and the United States (U.S.) MS patient responses from the U.S. were weighted for gender, age, region, race/ ethnicity, education, and income where necessary to align with actual proportions within the country Surveyed neurologists specializing in MS and who practice within the surveyed countries Neurologist responses in the U.S. were weighted for gender, region, and years in practice to align with actual proportions in the U.S. neurologist population NEUROLOGIST DEMOGRAPHICS v GENDER YEARS IN PRACTICE BASE n=900 BASE n=900 68% MALE 32% FEMALE 32 % 3 37 68 % % 20 % The remaining countries were not weighted individually; however, a global post-weight was applied to the total data in order to give each country equal weight 10 years or less 11-20 21-30 31+ OFFICE How would you describe your office or clinic? BASE n=418 31 % 41 % Solo practice Single-specialty partnership or group (2 or more physicians) Multi-specialty partnership or group (2 or more physicians) 2

TOP-LINE SURVEY RESULTS Understanding Communication Between MS and Their Patient and neurologist respondents were asked to respond to questions about patient/physician interaction with one another (for example, quality and comfort of relationship) and potential barriers to communication MS patients and physicians are generally satisfied with their conversations related to the disease: vi More than 8 in 10 patients who have seen a neurologist in the past year said they felt comfortable talking about their MS with their neurologists, characterizing their relationship as honest, open, comprehensive, and helpful Nearly all neurologists (96%) felt that they had an open dialogue with their patients, and 90% indicated that they have a good understanding of all aspects of their patients disease When asked if his or her neurologist is accessible and spends enough time with them, close to three-fourths of surveyed patients responded positively (71% and 74%, respectively) NEUROLOGISTS VIEW THEMSELVES VERY POSITIVELY Even more so than patients, neurologists also rate themselves very positively in terms of communication and relationships with patients PATIENTS VIEW COMMUNICATION POSITIVELY In general, patients rate their neurologist/ healthcare provider (HCP) well for honesty, openness, comprehensiveness, helpfulness, and knowledge and also for accessibility and availability, though slightly less so Patient/Neurologist Agreement With Statements About Communication and Relationships Percentage That Strongly/Somewhat Agree He/she is honest in setting my expectations for therapy success He/she has a good understanding of all aspects of my multiple sclerosis We have an open dialogue where I can ask any question I want He/she offers helpful info He/she does everything he/she can to manage my multiple sclerosis He/she makes sure I know everything I need and want to know He/she ensures I have a clear understanding of my options for therapy He/she spends enough time with me He/she is accessible when I need him/her BASE: QUALIFIED MS and Saw an HCP in the Past Year (Total n=927) Q930 How much do you agree or disagree with each of the following statements about your communication and relationship with your neurologist / the HCP you see the most for your MS? Q930 How much do you agree or disagree with each of the following statements about your communication and relationship with your multiple sclerosis patient? Please note that the patient responses are shown 7 7 8 90 % % Gap Neurologist Patient Patient Agreement With Statements About Communication and Relationship With Neurologist/HCP 71 % 81 % 81 % 80 % 7 85 % 82 % 8 97 % 9 97 % 9 95 % 97 % +12% +6% +14% +16% +15% +15% +18% +5% +18% Strongly Disagree Somewhat Disagree Somewhat Agree Strongly Agree He/she is honest in setting my expectations for therapy success He/she has a good understanding of all aspects of my multiple sclerosis We have an open dialogue where I can ask any question I want He/she offers helpful info He/she does everything he/she can to manage my multiple sclerosis He/she makes sure I know everything I need and want to know He/she ensures I have a clear understanding of my options for therapy He/she spends enough time with me He/she is accessible when I need him/her 8 % 7 % 18 % 20 % BASE: QUALIFIED MS and Saw an HCP in the Past Year (Total n=927) Q930 How much do you agree or disagree with each of the following statements about your communication and relationship with your neurologist / the HCP whom you see the most for your MS? Percentages may not always sum to total due to computer rounding 12 % 1 1 15 % 11 % 15 % 4 40 % 4 40 % 47 % 4 4 47 % 43 % 3 43 % 33 % 40 % Agree (NET) 85% 84% 82% 80% 79% 74% 71% in the U.S. and Spain are more likely than their counterparts to agree that they are accessible when their patients need them in the UK are the most likely to say that their neurologist/hcp is not accessible when they need him/her who are optimistic about their future, and those who are currently on a disease-modifying therapy (DMT), are more likely to agree with all statements than their respective counterparts in the U.S. are the most likely to say that their HCP spends enough time with them (87%) 3

TOP-LINE SURVEY RESULTS Despite Open Communication, Discomfort Remains in Discussing Typical Symptoms, Including Those That Are Private and Sensitive Nearly 1 in 5 patients who experience MS symptoms reported being uncomfortable speaking about difficulty walking (19%), tremors (19%), and muscle spasms (18%), which are characteristic symptoms of MS vii In addition, MS patients said that they are uncomfortable discussing more sensitive and private symptoms with their doctors, such as: vii tend to overestimate their patients discomfort talking about more sensitive and private topics such as sexual difficulties, bladder or bowel problems, mood swings, and cognitive issues, but tend to underestimate their discomfort discussing all other topics Sexual difficulties (54%) Bladder or bowel problems (28%) Mood swings (26%) Cognitive/memory issues (21%) Discomfort Reported in Discussing Symptoms Percentage of Reporting Discomfort Speaking With About Symptoms Percentage of Who Reported Symptoms as Uncomfortable for to Discuss % Gap Neurologist Patient +33 +26 +11-17 +16-16 -17-16 -13-14 -10-14 -11-10 -11-12 -11-10 N/A 5 87 % 5 37 % 37 % 2 21 % 21 % 1 1 18 % 17 % 17 % 1 1 1 15 % 15 % 1 13 % 12 % 3 % 2 % 2 % 4% 3 % 6% 2 % 5% 5 % 8 % 2 % 2 % 2 % N/A BASE: QUALIFIED MS WHO SAW A NEUROLOGIST IN THE PAST YEAR (Total = Variable) Q920 Which of the following symptoms, if any, are you not comfortable talking about with your neurologist and/or the healthcare provider you see the most for your multiple sclerosis? Q920 Which of the following symptoms, if any, do you think your MS patients are not comfortable talking about with you? 4

TOP-LINE SURVEY RESULTS MS and Identify Barriers to Effective Communication Nearly half of neurologists (47%) identified time as a barrier to effective communication with their patients. However, for patients, not wanting to be perceived as being difficult was cited as the most common barrier to effective dialogue (24%) viii in the U.S. are the least likely to say that they don t want to be seen as a difficult patient (14%) in Spain are the most likely to say that they hesitate to ask questions that they have (30%) in the U.S. are the least likely to say that they don t feel like they have enough time to discuss all of their patients concerns (35%), and patients in the U.S. are among the least likely to cite a lack of time to discuss their concerns as a barrier (14%) who feel that time is a communication barrier are more likely to wish that they had more information on most aspects of MS to provide to their patients than their counterparts He/she is honest in setting my expectations for therapy success. He/she has a good understanding of all aspects of my multiple sclerosis. We have an open dialogue where I can ask any question I want. He/she does everything he/she can to manage my multiple sclerosis. He/she makes sure I know everything I need and want to know. He/she ensures I have a clear understanding of my options for therapy. Barriers to Communication Percentage of and Who Selected Option As Barrier to Communication I don t want to be seen as a difficult patient Not enough time to discuss all of my concerns I hesitate to ask questions that I have I find it difficult to get in to see the doctor I sometimes avoid seeing the doctor, even if I have to He/she offers helpful info. I am overwhelmed by my diagnosis We are not a team/i have to figure things out on my own My doctor hasn t given me a clear idea of what s going on I feel like my doctor is often distracted My HCP s office is not conducive to having private conversations I don t ask for any information He/she spends enough time with me. I don t want to bring up issues having to do with my treatment He/she is accessible when I need him/her. I don t want any information Other Nothing N/A 11 % 3 % 7% 5 % 2 % 5 % 5 % 10 % 8 % 10 % 5 % 11% 12 % 1 13 % 12 % 1 2 22 % 21 % 47% 1 20 % 15 % 37 % 82% 96% 74% 79% 71% 85% 97% 84% 90% 40 % 80% 79% 95% 89% 97% 96% 97% % Gap Neurologist Patient -2% +26% +4% -2% +3% +28% -7% -5% N/A +2% +5% +2% +2% -3% -22% BASE: QUALIFIED MS and Saw an HCP in the Past Year (Total n=927) Q935 What, if anything, interferes with your communication with your neurologist / the healthcare provider you see the most for your MS? Q935 What, if anything, interferes with your communication with your multiple sclerosis patients? Please note that the patient responses are shown 5

Information Is Accessible, but More Is Needed TOP-LINE SURVEY RESULTS want more information on new developments in MS treatment and research (44%) ix Seventy-two percent of patients find online and social media resources most helpful for finding information about MS indicated a desire for additional resources about more private symptoms to provide to their MS patients, such as: Maintaining cognitive function (49%) Managing the emotional challenges of having MS (45%) Being sexually active (43%) ix Nearly 3 in 4 neurologists (72%) recommend patient support organizations to their patients who wish to learn more about the disease x SO WHAT INFORMATION IS DESIRED? most commonly want more information on new developments in MS treatment and research, but neurologists say that they would like to be able to provide their patients with more information on means for maintaining cognitive function in Germany and Spain are the most likely to mention means for maintaining cognitive functions (57% Germany, 52% Spain) in Spain are the most likely to say that they wish they had more information about how to find support groups for people with MS (49%) in the U.S. are the most likely to say that they wish they had more information about managing the cost of MS treatment (44%) Perhaps this is because U.S. patients most frequently mention cost when it comes to the greatest challenges that they face in managing their DMT (47%) What Information Is Desired by and? Percentage of and Who Indicated Desire for More Information on Aspects of MS New developments in MS treatment and research Managing MS symptoms Identifying new or subtle symptoms How to navigate and better understand the benefits/assistance that you're/they're eligible to receive The treatment options for MS available to me/them How to recognize relapses The clinical trials for MS available to me/them Means for maintaining cognitive functions Managing the emotional challenges of having MS How specific medications for MS work in my/their body Being sexually active with MS Managing the physical side effects of MS medication Managing the cost of MS treatment Managing MS in the workplace How to find support groups for people with MS Pregnancy-related topics Other I would not like any additional info about MS/ My patients do not request additional info about MS 25 % 21 % BASE: QUALIFIED MS (Total n=982) Q945 Which of the following aspects of multiple sclerosis, if any, would you like more information about? 3 Q947 Which of the following aspects of multiple sclerosis, if any, do you wish you had more information about to provide to your multiple sclerosis patients? 3 % 1 % 3 % 1 1 21 % 23 % 1 23 % 17 % 2 2 31 % 3 33 % 31 % 30 % 2 31 % 86% of patients would like more information about at least 1 aspect of MS Further, the lower the patients overall health, the more likely they are to want more information about aspects of MS: Excellent/Good: Fair: 85% Poor: 92% 3 4 43 % 42 % 45 % 4 6

GLOBAL SURVEY FACT SHEET STATE OF MS CONSORTIUM Patient Advocacy Group Representatives: Europe: Maggie Alexander, chief executive, European MS Platform, represents 39 MS societies from 34 European countries United States: Nancy Law, executive vice president, National MS Society : Germany: Robert Weissert, M.D., Ph.D., senior physician and researcher, university professor of Clinical Neurobiology, University of Regensburg Italy: Antonio Uccelli, M.D., associate professor of Neurology and head of MS Clinic and Neuroimmunology Unit, University of Genoa Spain Mar Tintore, M.D., Ph.D., senior consultant neurologist, Neurology-Neuroimmunology Department, MS Centre of Catalonia, Hospital Vall d Hebron United Kingdom: Martin Duddy, M.D., consultant neurologist, Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne United States: David E. Jones, M.D., assistant professor, University of Virginia Health System, Charlottesville, Virginia Sibyl Wray, M.D., director, Hope Neurology MS Center, Knoxville, Tennessee REFERENCES i. Multiple Sclerosis International Federation, Atlas of MS 2013. Epidemiology of MS. Page 8. Date Accessed: July 9, 2014. http://www.msif.org/includes/documents/cm_docs/2013/m/msif-atlas-of-ms-2013-report.pdf?f=1 ii. Multiple Sclerosis International Federation. Atlas of MS 2013. Epidemiology of MS. Date Accessed: July 9, 2014. http://www.atlasofms.org/query.aspx iii. NMSS. MS Prevalence. Date Accessed: July 9, 2014. http://www.nationalmssociety.org/about-the-society/msprevalence/index.aspx iv. Data on file with Harris Poll. DSQ Q268, Q280, Q607, Q705. Data available upon request v. Data on file with Harris Poll, DSQ Q8702. Q8712, Q8719. Data available upon request vi. Data on file with Harris Poll, DSQ Q930 Data available upon request vii. Data on file with Harris Poll, DSQ Q920 Data available upon request viii. Data on file with Harris Poll, DSQ Q935 Data available upon request ix. Data on file with Harris Poll, DSQ Q945 Data available upon request x. Data on file with Harris Poll, DSQ Q940 Data available upon request 7